A prospective double-blind trial of intracorporeal papaverine versus prostaglandin E1 in the treatment of impotence

M. F. Sarosdy, C. H. Hudnall, D. R. Erickson, T. C. Hardin, D. E. Novicki

Research output: Contribution to journalArticlepeer-review

37 Scopus citations

Abstract

A randomized prospective, double-blind clinical trial was performed comparing intracorporeal injections of papaverine (30 mg. per ml.) with prostaglandin E1 (10 mcg. per ml.) as pharmacological treatment of impotence. A total of 15 men completed the study, receiving papaverine and prostaglandin E1 in a crossover design. Over-all, 9 of 15 evaluable patients had a full erection with either 1 or both drugs: 3 secondary to papaverine only, 2 to prostaglandin E1 only, and 4 to both drugs. No major complications were observed. We conclude that intracorporeal prostaglandin E1 may be used successfully to stimulate pharmacological erections and that it might be useful in patients not responding to intracorporeal papaverine.

Original languageEnglish
Pages (from-to)551-553
Number of pages3
JournalJournal of Urology
Volume141
Issue number3 I
DOIs
StatePublished - 1989

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'A prospective double-blind trial of intracorporeal papaverine versus prostaglandin E1 in the treatment of impotence'. Together they form a unique fingerprint.

Cite this